Health

Photo

Health care sector gears up for U.S. reform

NEW YORK (Reuters) - Drug makers, insurers and other health care companies are preparing for possibly dramatic changes to the U.S. health care system as Democrats increase their power in Washington next year.

Continue Reading

More money and strong leader wanted at FDA

NEW YORK (Reuters) - Drug makers are calling for steady leadership, political independence and a boost in funding to improve the climate at the U.S. Food and Drug Administration under President-elect Barack Obama.

Pharma overhaul under way ahead of challenges

NEW YORK (Reuters) - Leaders of the world's largest drug makers are all under the hood working to overhaul a rusty business model, even as they differ over the right new parts.

Daiichi confident of Effient approval

NEW YORK (Reuters) - Daiichi-Sankyo's top U.S. executive expressed confidence that the blood clot preventer it is developing with Eli Lilly & Co will soon win U.S. approval, and said the sales force for the medicine was champing at the bit to get started. | Video

Walgreen makes Times Square return as it revamps

CHICAGO (Reuters) - Walgreen Co has more than 6,500 drugstores across the United States, but only one of them can help the chain reach billions of people, even if they never step inside. | Video

Pharmaceuticals can't escape recessionary chill

NEW YORK (Reuters) - It may still carry a defensive tag, but the pharmaceuticals industry won't escaped unscathed as economies around the world are pitched into recession.

Is biotech really such a bargain?

NEW YORK (Reuters) - Cash-strapped biotechs may be hoping Big Pharma rides to the rescue, but they shouldn't count on it.

Pfizer pegs growth to overseas, older drugs

NEW YORK (Reuters) - Pfizer Inc's top executive is counting on higher sales in emerging markets and revenue from older medicines to generate enough revenue in the next three years to help offset an expected plunge in sales of its top selling Lipitor cholesterol drug.

Pfizer, others still chasing obesity drugs

NEW YORK (Reuters) - After pulling the plug on an experimental obesity drug from a troubled class of medicines, Pfizer Inc's Chief Executive Jeff Kindler said the world's largest drug maker would continue to pursue treatments for the emerging health crisis.

Pfizer CEO: Independence needed at FDA

NEW YORK (Reuters) - The U.S. Food and Drug Administration was hurt by turnover at the top during the George W. Bush administration and needs a strong, independent leader, Pfizer Inc Chief Executive Jeff Kindler said on Thursday.

Quotes from the Health Summit: Thursday

NEW YORK (Reuters) - Following are selected quotes from executives speaking at the Reuters Health Summit, being held in New York through November 20.

Speakers

Reporter's Notebook

» More from Summits Blogs

Upcoming Summits

Summit Date Category
Islamic Banking and Finance Feb 15 - 18 Country Summits
Travel and Leisure Feb 22 - 24 Hotels/Casinos
Private Equity and Hedge Funds Mar 1 - 3 Financial Services/Exchanges
Global Mining and Steel Mar 8 - 10 Mining
Food and Agriculture Mar 15 - 18 Mining
Canadian Oil Sands Mar 22 - 23 Energy
Funds Mar 23 - 24 Financial Services/Exchanges
Global Exchanges and Trading Mar 29 - 31 Financial Services / Exchanges
Financial Regulation Apr 26 - 29 Financial Services / Exchanges
» Download Summit Calendar